Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-19-042891
Filing Date
2019-11-12
Accepted
2019-11-12 16:02:18
Documents
59
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q stok-10q_20190930.htm 10-Q 1885908
2 EX-31.1 stok-ex311_6.htm EX-31.1 15919
3 EX-31.2 stok-ex312_11.htm EX-31.2 15967
4 EX-32.1 stok-ex321_8.htm EX-32.1 7917
5 EX-32.2 stok-ex322_9.htm EX-32.2 7883
  Complete submission text file 0001564590-19-042891.txt   4800738

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT stok-20190930.xml EX-101.INS 748612
7 XBRL TAXONOMY EXTENSION SCHEMA stok-20190930.xsd EX-101.SCH 41929
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE stok-20190930_cal.xml EX-101.CAL 31076
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE stok-20190930_def.xml EX-101.DEF 107766
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE stok-20190930_lab.xml EX-101.LAB 269278
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE stok-20190930_pre.xml EX-101.PRE 207646
Mailing Address 3 PRESTON COURT BEDFORD MA 01730
Business Address 3 PRESTON COURT BEDFORD MA 01730 781-430-8200
Stoke Therapeutics, Inc. (Filer) CIK: 0001623526 (see all company filings)

EIN.: 471144582 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38938 | Film No.: 191209197
SIC: 2834 Pharmaceutical Preparations